(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

With the CSF-1R inhibitor space heating up, Merck KGaA ... license to the drug. The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals ... Novo Nordisk is paying $200 million upfront to United Laboratories for obesity drug UBT251. Bayer ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.

Experimental Lilly Drug Cuts Genetic Heart Disease Risk Factor by 94% in Trial ... in clinical trials. Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...